StockData
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. (NRSN) stock

NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$1.51−0.05 (-3.51%)

Close on Nov 17, 2026Market cap $2.77MP/E –Yield –

NeuroSense Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $6.23M, up 9.3% from the year before. The highest annual figure on record is $7.27M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.23M+9.3%
FY2024Dec 31, 2024$5.70M-21.7%
FY2023Dec 31, 2023$7.27M+30.2%
FY2022Dec 31, 2022$5.59M+300.8%
FY2021Dec 31, 2021$1.39M–

More NeuroSense Therapeutics figures

See a number that looks wrong?